<DOC>
	<DOCNO>NCT02231008</DOCNO>
	<brief_summary>The aim study investigate tasimelteon vs. placebo sleep disturbance individual Smith-Magenis Syndrome .</brief_summary>
	<brief_title>Evaluating Effects Tasimelteon v Placebo Sleep Disturbances SMS</brief_title>
	<detailed_description />
	<mesh_term>Smith-Magenis Syndrome</mesh_term>
	<criteria>1 . A confirmed clinical diagnosis SMS 2 . Informed consent patient legal guardian 3 . Male female age 16 65 year age 4 . History sleep disturbance 5 . Willing able comply study requirement restriction 1 . Unable dose daily medication appoint caregiver complete require outpatient assessment 2 . Exposure investigational drug , include placebo , within 30 day 5 halflives ( whichever longer ) screen 3 . Any sound medical reason determine clinical investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>SMS</keyword>
</DOC>